Skip to main
CYBN

Cybin (CYBN) Stock Forecast & Price Target

Cybin (CYBN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cybin Inc is experiencing accelerated commercial readiness efforts across its therapeutic programs, positioning the company favorably for future launches in the interventional psychiatry space. With a strong foundation in clinical execution, commercial groundwork, and enhanced financial stability, Cybin is well-prepared for two major data readouts anticipated in 2026. Furthermore, the successful completion of the Phase 2 CYB004 generalized anxiety disorder trial and continued advancements in the Phase 3 CYB003 major depressive disorder program highlight the company's ongoing progress and commitment to developing effective mental health treatments.

Bears say

Cybin Inc. faces a negative outlook due to multiple fundamental challenges, including the complexities involved in developing neuropsychiatric products, which have high risks of clinical trial failures and unproven safety and efficacy of its psychedelic compounds. The company's recent dilution from capital-raising efforts has negatively impacted its discounted cash flow (DCF) valuation, causing a significant decrease in the projected price target. Furthermore, uncertainties regarding regulatory approval, intellectual property protection, and market acceptance of psychedelic therapies heighten the risk profile, making the commercial viability of Cybin's products uncertain.

Cybin (CYBN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cybin (CYBN) Forecast

Analysts have given Cybin (CYBN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cybin (CYBN) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cybin (CYBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.